Please login to the form below

Not currently logged in
Email:
Password:

Docetaxel

This page shows the latest Docetaxel news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

not yet approved for prostate cancer but making its way through late-stage testing – as well as chemotherapy with docetaxel and prednisone, and hormone therapy with Astellas/Pfizer’s Xtandi (enzalutamide)

Latest news

More from news
Approximately 1 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    In China there has been a rise in the use of Xeloda in combination with docetaxel as a second and third-line treatment.

  • Pharma deals during April 2013 Pharma deals during April 2013

    Bind more than $180.5m plus tiered royalties. And if that were not enough, the biotech recently secured $20m from its venture backers to fund phase II work on its

  • Detecting and managing NS

    Supported by sanofi-aventis, Succinct worked in close partnership with the UK Oncology Nursing Society (UKONS) to develop a range of patient-centred materials for those women receiving Taxotere (docetaxel) for

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics